Enfusion (Enfusion) ROCE % : 9.81% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Enfusion ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Enfusion's annualized ROCE % for the quarter that ended in Dec. 2023 was 9.81%.

Enfusion ROCE % Historical Data

The historical data trend for Enfusion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enfusion ROCE % Chart

Enfusion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

91.66

27.88

-436.43

-11.71

12.25

Enfusion Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial											5.23	17.48	10.40	12.99	9.81

Enfusion ROCE % Calculation

Enfusion's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	11.948	/	( ( (123.783 - 17.38)	+	(108.972 - 20.309) )	/ 2 )
	=	11.948	/	( (106.403	+	88.663)	/ 2 )
	=	11.948	/	97.533
	=	12.25 %

Enfusion's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	8.536	/	( ( (101.74 - 16.373)	+	(108.972 - 20.309) )	/ 2 )
	=	8.536	/	( ( 85.367	+	88.663 )	/ 2 )
	=	8.536	/	87.015
	=	9.81 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Enfusion (NYSE:ENFN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Enfusion ROCE % Related Terms

Thank you for viewing the detailed overview of Enfusion's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Enfusion (Enfusion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Enfusion Inc (NYSE:ENFN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

125 South Clark Street, Suite 750, Chicago, IL, USA, 60603

Website

https://www.enfusion.com

Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.

Executives

Deirdre Somers	director	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Bradley Herring	officer: Chief Financial Officer	C/O SHIFT4 PAYMENTS, INC., 2202 N. IRVING STREET, ALLENTOWN PA 16109
Oleg Movchan	director, 10 percent owner	C/O ENFUSION INC., 125 SOUTH CLARK ST. STE 750, CHICAGO IL 60603
Bronwen Bastone	officer: Chief People Officer	C/O ENFUSION, INC., 125 SOUTH CLARK STREET SUITE 750, CHICAGO IL 60603
Stephen Malherbe	10 percent owner	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Dan Groman	officer: Chief Technology Officer	C/O ENFUSION INC., 125 SOUTH CLARK STREET STE. 750, CHICAGO IL 60603
Tarek Hammoud	10 percent owner	C/O ENFUSION INC., 125 SOUTH CLARK ST. STE. 750, CHICAGO IL 60603
Ftv Investment Holdings, L.p.	10 percent owner	601 CALIFORNIA STREET, FLOOR 19, SAN FRANCISCO CA 94108
Michael Spellacy	director	399 PARK AVENUE, NEW YORK NY 10022
Quiet Light Securities, Llc	10 percent owner	70 WEST MADISON, SUITE 1675, CHICAGO IL 60602
Steven M. Bachert	officer: Chief Revenue Officer	C/O ENFUSION INC., 125 SOUTH CLARK ST., STE 750, CHIGAGO IL 60603
Lra Ventures, Llc	10 percent owner	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Hillhouse Investment Management, Ltd.	10 percent owner	OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Roy Luo	director	394 PACIFIC AVENUE, 2ND FLOOR, SAN FRANCISCO CA 94111
Iconiq Strategic Partners V-b, L.p.	10 percent owner	394 PACIFIC AVENUE, SECOND FLOOR, SAN FRANCISCO CA 94111